{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:11:38Z","timestamp":1761016298553},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1007\/s00115-004-1696-5","type":"journal-article","created":{"date-parts":[[2004,3,22]],"date-time":"2004-03-22T14:58:36Z","timestamp":1079967516000},"page":"749-754","source":"Crossref","is-referenced-by-count":6,"title":["Levetiracetam in der Kombinationsbehandlung fokaler Epilepsien","Levetiracetam in combined therapy for focal epilepsy: experience with 80 patients"],"prefix":"10.1007","volume":"75","author":[{"given":"Andreas","family":"Schulze-Bonhage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Feil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Homberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1696_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1059-1311(02)00292-3","volume":"12","author":"Abou-Khalil","year":"2003","unstructured":"Abou-Khalil B, Hemdal P, Privitera MD (2003) An open-label study of levetiracetam at individualised doses between 1,000 and 3,000\u00a0mg day\u22121 in adult patients with refractory epilepsy. Seizure 12:141\u2013149","journal-title":"Seizure"},{"key":"1696_CR2","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1001\/archneur.59.12.1905","volume":"59","author":"Bazil","year":"2002","unstructured":"Bazil CW, Rose A, Resor S et al. (2002) Levetiracetam may be more effective for late-onset partial epilepsy. Arch Neurol 59:1905\u20131908","journal-title":"Arch Neurol"},{"key":"1696_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1059-1311(03)00004-9","volume":"12","author":"Bello-Espinosa","year":"2003","unstructured":"Bello-Espinosa LE, Roberts SL (2003) Levetiracetam for benign epilepsy of childhood with centrotemporal spikes\u2014three cases. Seizure 12:157\u2013159","journal-title":"Seizure"},{"key":"1696_CR4","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","volume":"41","author":"Ben-Menachem","year":"2000","unstructured":"Ben-Menachem E, Falter U (2000) Efficacy and tolerability of levetiracetam 3,000\u00a0mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 41:1276\u20131283","journal-title":"Epilepsia"},{"key":"1696_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0920-1211(02)00247-4","volume":"53","author":"Ben-Menachem","year":"2003","unstructured":"Ben-Menachem E, Edrich P, van Vleymen B et al. (2003) Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res 53:57\u201364","journal-title":"Epilepsy Res"},{"key":"1696_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1053\/seiz.2000.0380","volume":"9","author":"Betts","year":"2000","unstructured":"Betts T, Waegemans T, Crawford P (2000) A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2,000\u00a0mg daily and 4,000\u00a0mg daily, without titration in patients with refractory epilepsy. Seizure 9:80\u201387","journal-title":"Seizure"},{"key":"1696_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1059-1311(02)00258-3","volume":"12","author":"Betts","year":"2003","unstructured":"Betts T, Yarrow H, Greenhill L et al. (2003) Clinical experience of marketed Levetiracetam in an epilepsy clinic\u2014a one year follow up study. Seizure 12:136\u2013140","journal-title":"Seizure"},{"key":"1696_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0920-1211(02)00106-7","volume":"51","author":"Bialer","year":"2002","unstructured":"Bialer M, Johannessen SI, Kupferberg HJ et al. (2002) Progress report on new antiepileptic drugs: a summary of the sixth Eilat conference (EILAT VI). Epilepsy Res 51:31\u201371","journal-title":"Epilepsy Res"},{"key":"1696_CR9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-1211(01)00323-0","volume":"48","author":"Boon","year":"2002","unstructured":"Boon P, Chauvel P, Pohlmann-Eden B et al. (2002) Dose-response effect of levetiracetam 1,000 and 2,000\u00a0mg\/day in partial epilepsy. Epilepsy Res 48:77\u201389","journal-title":"Epilepsy Res"},{"key":"1696_CR10","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1159\/000006657","volume":"55","author":"Cereghino","year":"2000","unstructured":"Cereghino JJ, Biton V, Abou-Khalil B et al. (2000) Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial. Neurology 55:236\u2013242","journal-title":"Neurology"},{"key":"1696_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S1059-1311(02)00273-X","volume":"12","author":"Cohen","year":"2003","unstructured":"Cohen J (2003) Levetiracetam monotherapy for primary generalised epilepsy. Seizure 12:150\u2013153","journal-title":"Seizure"},{"key":"1696_CR12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S1525-5050(03)00005-2","volume":"4","author":"Cramer","year":"2003","unstructured":"Cramer JA, DeRue K, Devinsky O et al. (2003) A systematic review of the behavioural effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epil Behav 4:124\u2013132","journal-title":"Epil Behav"},{"key":"1696_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.yebeh.2003.07.008","volume":"4","author":"Dinkelacker","year":"2003","unstructured":"Dinkelacker V, Dietl T, Widman G et al. (2003) Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epil Behav 4:537\u2013547","journal-title":"Epil Behav"},{"key":"1696_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0920-1211(01)00296-0","volume":"47","author":"French","year":"2001","unstructured":"French J, Edrich P, Cramer JA (2001) A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res 47:77\u201390","journal-title":"Epilepsy Res"},{"key":"1696_CR15","first-page":"187","volume":"43","author":"Gates","year":"2002","unstructured":"Gates JR, Folland C, Berhovw J et al. (2002) Behavioral side-effects of levetiracetam. Epilepsia 43(S7):187","journal-title":"Epilepsia"},{"key":"1696_CR16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1034\/j.1600-0404.2003.02141.x","volume":"107","author":"Gelisse","year":"2003","unstructured":"Gelisse P, Crespel A, Genton P et al. (2003) Dramatic effect of levetiracetam on epileptic negative myoclonus. Acta Neurol Scand 107:302\u2013303","journal-title":"Acta Neurol Scand"},{"key":"1696_CR17","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1046\/j.1528-1157.2002.13101.x","volume":"43","author":"Glauser","year":"2002","unstructured":"Glauser TA, Pellock JM, Bebin EM et al. (2002) Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 43:518\u2013524","journal-title":"Epilepsia"},{"key":"1696_CR18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1046\/j.1528-1157.2002.18101.x","volume":"43","author":"Glien","year":"2002","unstructured":"Glien M, Brandt C, Potschka H et al. (2002) Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 43:350\u2013357","journal-title":"Epilepsia"},{"key":"1696_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0920-1211(95)00077-1","volume":"22","author":"Gower","year":"1995","unstructured":"Gower AJ, Hirsch E, Boehrer A et al. (1995) Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 22:207\u2013213","journal-title":"Epilepsy Res"},{"key":"1696_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0920-1211(00)00158-3","volume":"42","author":"Grant","year":"2000","unstructured":"Grant R, Shorvon SD (2000) Efficacy and tolerability of 1,000\u20134,000\u00a0mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy Res 42:89\u201395","journal-title":"Epilepsy Res"},{"key":"1696_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1046\/j.1528-1157.2001.00008.x","volume":"42","author":"Harden","year":"2001","unstructured":"Harden C (2001) Safety profile of levetiracetam. Epilepsia 42(S4):36\u201339","journal-title":"Epilepsia"},{"key":"1696_CR22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0014-2999(98)00410-5","volume":"353","author":"Klitgaard","year":"1998","unstructured":"Klitgaard H, Matagne A, Gobert J et al. (1998) Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353:191\u2013206","journal-title":"Eur J Pharmacol"},{"key":"1696_CR23","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1046\/j.1528-1157.2001.32101.x","volume":"42","author":"Kossoff","year":"2001","unstructured":"Kossoff EH, Bergey GK, Freeman J et al. (2001) Levetiracetam psychosis in children with epilepsy. Epilepsia 42:1611\u20131613","journal-title":"Epilepsia"},{"key":"1696_CR24","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/WNL.56.12.1772","volume":"56","author":"Krakow","year":"2001","unstructured":"Krakow K, Walker M, Otoul C et al. (2001) Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 56:1772\u20131774","journal-title":"Neurology"},{"key":"1696_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0014-2999(93)90768-D","volume":"232","author":"L\u00f6scher","year":"1993","unstructured":"L\u00f6scher W, H\u00f6nack D (1993) Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 232:147\u2013158","journal-title":"Eur J Pharmacol"},{"key":"1696_CR26","first-page":"82","volume":"42","author":"Matagne","year":"2001","unstructured":"Matagne AC, Baltes E, Coupez R et al. (2001) Levetiracetam enhances markedly the seizure suppression of other antiepileptic drugs in audiogenic susceptible mice. Epilepsia 42(S7):82","journal-title":"Epilepsia"},{"key":"1696_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0920-1211(03)00080-9","volume":"54","author":"Morrell","year":"2003","unstructured":"Morrell MJ, Leppik I, French J et al. (2003) The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 54:153\u2013161","journal-title":"Epilepsy Res"},{"key":"1696_CR28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0014-2999(95)00436-O","volume":"286","author":"Noyer","year":"1995","unstructured":"Noyer M, Gillard M, Matagne A et al. (1995) The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 286:137\u2013146","journal-title":"Eur J Pharmacol"},{"key":"1696_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","volume":"85","author":"Patsalos","year":"2000","unstructured":"Patsalos PN (2000) Pharmacokinetic profile of levetiracetam: towards ideal characteristics. Pharmacol Therap 85:77\u201385","journal-title":"Pharmacol Therap"},{"key":"1696_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0920-1211(02)00250-4","volume":"53","author":"Perrucca","year":"2003","unstructured":"Perrucca E, Gidal BE, Balt\u00e8s E (2003) Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive theapy trials. Epilepsy Res 53:47\u201356","journal-title":"Epilepsy Res"},{"key":"1696_CR31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1053\/seiz.2001.0497","volume":"10","author":"Rijckevorsel","year":"2001","unstructured":"Rijckevorsel K (2001) The \u2018number needed to treat\u2019 with levetiracetam (LEV): comparison with the other new antiepileptic drugs (AEDs). Seizure 10:235\u201326","journal-title":"Seizure"},{"key":"1696_CR32","first-page":"151","volume":"43","author":"Sadek","year":"2002","unstructured":"Sadek A, Fix A, French J (2002) Levetiracetam-related behavioural adverse effects: a post-marketing study. Epilepsia 43(S8):151","journal-title":"Epilepsia"},{"key":"1696_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0920-1211(02)00179-1","volume":"51","author":"Schmidt","year":"2002","unstructured":"Schmidt D, Elger CE, Holmes GL (2002) Pharmacological over-treatment in epilepsy. Epilepsy Res 51:1-12","journal-title":"Epilepsy Res"},{"key":"1696_CR34","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/0896-6974(96)00010-2","volume":"9","author":"Sharief","year":"1996","unstructured":"Sharief M, Singh P, Sander J et al. (1996) Efficacy and tolerability study of ucb L059 in patients with refractory epilepsy. J Epilepsy 9:106\u2013112","journal-title":"J Epilepsy"},{"key":"1696_CR35","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","volume":"41","author":"Shorvon","year":"2000","unstructured":"Shorvon SD, L\u00f6wenthal A, Janz D et al. (2000) Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41:1179\u20131186","journal-title":"Epilepsia"},{"key":"1696_CR36","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0163-7258(95)00021-6","volume":"67","author":"Walker","year":"1995","unstructured":"Walker MC, Patsalos PN (1995) Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther 67:351\u2013384","journal-title":"Pharmacol Ther"},{"key":"1696_CR37","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1212\/01.WNL.0000091865.46063.67","volume":"61","author":"White","year":"2003","unstructured":"White JR; Walczak TS, Leppik IE et al. (2003) Discontinuation of levetiracetam because of behavioural side effects. Neurology 61:1218\u20131221","journal-title":"Neurology"},{"key":"1696_CR38","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1053\/seiz.2000.0504","volume":"10","author":"Zona","year":"2001","unstructured":"Zona C, Niespodziany I, Marchetti C et al. (2001) Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure 10:279\u2013286","journal-title":"Seizure"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-004-1696-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-004-1696-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-004-1696-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-004-1696-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T05:09:53Z","timestamp":1699506593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-004-1696-5"}},"subtitle":["Erfahrungen bei 80 Patienten"],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["1696"],"URL":"https:\/\/doi.org\/10.1007\/s00115-004-1696-5","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"type":"print","value":"0028-2804"},{"type":"electronic","value":"1433-0407"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}